Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM559 in healthy subjects
NCT07175506Phase 1Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CM559 in Alzheimer's disease (AD) (5 cohorts), sponsored by Keymed Biosciences. Primary endpoints: Adverse Events at 99 days, Physical Examinations at 99 days and 4 more. Started Sep 2025; status: recruiting.
02
Drugs
CM559
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07175506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07175506.